Skip to main content
. Author manuscript; available in PMC: 2024 Dec 9.
Published in final edited form as: Nat Genet. 2022 Jun 16;54(7):950–962. doi: 10.1038/s41588-022-01097-w

Fig. 8. Slc47a1 loss confers kidney disease risk in mice.

Fig. 8.

a. Experimental scheme of the cisplatin-induced kidney injury model in wild type (Slc47a1+/+) and Slc47a1 knockout (Slc47a1−/−) mice.

b. The relative expression of Slc47a1 (y-axis) in kidneys of Slc47a1+/+and Slc47a1−/− mice treated with cisplatin (Cis) or sham (CTR).

c. Serum creatinine levels (y-axis) in control or cisplatin treated Slc47a1+/+and Slc47a1−/− mice.

d. Serum BUN levels (y-axis) in control or cisplatin treated Slc47a1+/+and Slc47a1−/− mice.

e. Representative image (left panel) and quantification (right panel) of Hematoxylin and eosin (H&E) stained kidney sections of control or cisplatin treated Slc47a1+/+and Slc47a1−/− mice. Scale bars: 20μm.

f. The relative expression of injury markers Lipocalin 2 (Ngal) and kidney injury molecule 1 (Kim1) (y-axis) in kidneys of control or cisplatin treated Slc47a1+/+and Slc47a1−/− mice.

g. Representative image (left panel) and quantification (right panel) of Sirius red stained kidney sections of control or cisplatin treated Slc47a1+/+and Slc47a1−/− mice. Scale bar: 20μm.

h. The relative expression of fibrosis markers; Collagen 1 (Col1a1) and Vimentin (Vim) in kidneys of control or cisplatin treated Slc47a1+/+and Slc47a1−/− mice.

i. Representative western blot image (top panel) and quantification (bottom panel) of Receptor interacting serine/threonine kinase 3 (RIPK3), NLR family pyrin domain containing 3 (NLRP3), Actin alpha 2 (aSMA) in kidney of control or cisplatin treated Slc47a1+/+and Slc47a1−/− mice. GAPDH was used as a control.

j. Relative expression of markers of inflammation; Chemokine ligand 2 (Ccl2) and Tumor necrosis factor (Tnfa) in kidneys of control or cisplatin treated Slc47a1+/+and Slc47a1−/− mice.

k. Relative expression of cell death and inflammation marker genes; Receptor interacting serine/threonine kinase 1 (Ripk1), Ripk3 and Mixed lineage kinase domain like pseudokinase (Mlkl) in kidney from Slc47a1+/+and Slc47a1−/− mice treated with or without repeated cisplatin.

P values were calculated by one-way ANOVA with post hoc Tukey test (b-k, n=4 biologically independent Slc47a1+/+ cisplatin mice examined over n=3 independent Slc47a1+/+ control; n=5 biologically independent Slc47a1−/− cisplatin mice examined over n=4 independent Slc47a1+/+ cisplatin mice). n.s., not significant. Quantitative data are presented as mean ± SD.